Background pattern of a brain with neural connections

Team Bronstein

Environmental & Genetic Determinants of Parkinson’s Disease Progression

2026-Present

Environmental and genetic factors confer not only Parkinson’s disease (PD) onset but may also underlie heterogeneity in PD progression. We will utilize a well-established PD cohort, patient-derived stem cells, and novel animal models to determine the mechanisms by which environmental toxins accelerate disease progression and identify genetic factors that confer individual vulnerability to rapid progression, using pathological alpha-synuclein transmission as a key biological index of progression. We will focus on two specific pesticides copper sulphate and 2,4-D that we have linked to faster symptom progression, and air pollution, which is increasingly recognized as a key risk factor for PD.

Tags
Environmental toxinsPD progressionPesticides

Contributions

Stay tuned—this is where the team’s scientific contributions will be shared.

Accolades

Check back soon to see how this team is being recognized.

In the News

Decoding the Blueprint: Advancing Personalized Parkinson’s Treatments

Decoding the Blueprint: Advancing Personalized Parkinson’s Treatments

05/21/2026 — In our community, we often hear: “If you’ve met one person with Parkinson’s, you’ve met one person with Parkinson’s.” This isn’t just an adage — it’s a biological reality. This radical variability is exactly what makes the disease so difficult to outsmart. We’ve learned that a puzzle this fragmented cannot be solved with a single, broad stroke. Our goal isn’t to find one answer for everyone, but the right answer for the right person at the right time.

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

04/28/2026 — Today, Aligning Science Across Parkinson’s (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.